» Articles » PMID: 24771333

Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-infected Patients

Abstract

Background: Patterns of cause-specific mortality in individuals infected with human immunodeficiency virus type 1 (HIV-1) are changing dramatically in the era of antiretroviral therapy (ART).

Methods: Sixteen cohorts from Europe and North America contributed data on adult patients followed from the start of ART. Procedures for coding causes of death were standardized. Estimated hazard ratios (HRs) were adjusted for transmission risk group, sex, age, year of ART initiation, baseline CD4 count, viral load, and AIDS status, before and after the first year of ART.

Results: A total of 4237 of 65 121 (6.5%) patients died (median, 4.5 years follow-up). Rates of AIDS death decreased substantially with time since starting ART, but mortality from non-AIDS malignancy increased (rate ratio, 1.04 per year; 95% confidence interval [CI], 1.0-1.1). Higher mortality in men than women during the first year of ART was mostly due to non-AIDS malignancy and liver-related deaths. Associations with age were strongest for cardiovascular disease, heart/vascular, and malignancy deaths. Patients with presumed transmission through injection drug use had higher rates of all causes of death, particularly for liver-related causes (HRs compared with men who have sex with men: 18.1 [95% CI, 6.2-52.7] during the first year of ART and 9.1 [95% CI, 5.8-14.2] thereafter). There was a persistent role of CD4 count at baseline and at 12 months in predicting AIDS, non-AIDS infection, and non-AIDS malignancy deaths. Lack of viral suppression on ART was associated with AIDS, non-AIDS infection, and other causes of death.

Conclusions: Better understanding of patterns of and risk factors for cause-specific mortality in the ART era can aid in development of appropriate care for HIV-infected individuals and inform guidelines for risk factor management.

Citing Articles

Cardiac and Renal Comorbidities in Aging People Living With HIV.

McCutcheon K, Nqebelele U, Murray L, Thomas T, Mpanya D, Tsabedze N Circ Res. 2024; 134(11):1636-1660.

PMID: 38781295 PMC: 11122746. DOI: 10.1161/CIRCRESAHA.124.323948.


Demographic and clinical factors correlated with clinical outcomes among people with HIV treated by antiretroviral therapy: a retrospective cohort study.

Li Y, Liu H, Zhang S, Zhang Y, Wang H, Zhang H BMC Infect Dis. 2024; 24(1):514.

PMID: 38778273 PMC: 11112820. DOI: 10.1186/s12879-024-09406-w.


Health-Related Quality of Life in People with Advanced HIV Disease, from 1996 to 2021: Systematic Review and Meta-analysis.

Portilla-Tamarit I, Rubio-Aparicio M, Fuster-RuizdeApodaca M, Portilla-Tamarit J, Reus S, Portilla J AIDS Behav. 2024; 28(6):1978-1998.

PMID: 38743382 PMC: 11161547. DOI: 10.1007/s10461-024-04298-y.


Evolving AIDS- and non-AIDS Mortality and Predictors in the PISCIS Cohort of People Living With HIV in Catalonia and the Balearic Islands (Spain), 1998-2020.

Nomah D, Jamarkattel S, Bruguera A, Moreno-Fornes S, Diaz Y, Alonso L Open Forum Infect Dis. 2024; 11(4):ofae132.

PMID: 38560603 PMC: 10977910. DOI: 10.1093/ofid/ofae132.


Survival analysis of PLWHA undergoing combined antiretroviral therapy: exploring long-term prognosis and influencing factors.

Pu J, Wu J Front Public Health. 2024; 12:1327264.

PMID: 38454987 PMC: 10917938. DOI: 10.3389/fpubh.2024.1327264.


References
1.
Hogg R, Yip B, Chan K, Wood E, Craib K, OShaughnessy M . Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001; 286(20):2568-77. DOI: 10.1001/jama.286.20.2568. View

2.
Lohse N, Gerstoft J, Kronborg G, Larsen C, Pedersen C, Pedersen G . Comorbidity acquired before HIV diagnosis and mortality in persons infected and uninfected with HIV: a Danish population-based cohort study. J Acquir Immune Defic Syndr. 2011; 57(4):334-9. DOI: 10.1097/QAI.0b013e31821d34ed. View

3.
Tate J, Justice A, Hughes M, Bonnet F, Reiss P, Mocroft A . An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS. 2012; 27(4):563-72. PMC: 4283204. DOI: 10.1097/QAD.0b013e32835b8c7f. View

4.
May M, Ingle S, Costagliola D, Justice A, de Wolf F, Cavassini M . Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). Int J Epidemiol. 2013; 43(3):691-702. PMC: 4052127. DOI: 10.1093/ije/dyt010. View

5.
May M, Gompels M, Delpech V, Porter K, Post F, Johnson M . Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ. 2011; 343:d6016. PMC: 3191202. DOI: 10.1136/bmj.d6016. View